Dren Bio and Novartis link on bispecific antibodies for cancer

Dren Bio has entered a strategic partnership with Novartis Pharma to develop therapeutic bispecific antibodies to treat cancer.

Related Posts

Galecto terminates development for its lead candidate

Aug 16, 2023

Providers still hesitate to prescribe buprenorphine for...

Jul 22, 2023

What health policies could hitch a ride on a spending b...

Nov 15, 2023